Answers are grounded in this paper and cite their sources.
CD24 is a heavily glycosylated surface protein reportedly expressed across a broad range of solid and hematological malignancies, making it an attractive candidate antigen for chimeric antigen receptor (CAR) T-cell therapy. Using publicly available datasets, we confirmed that CD24 is broadly expressed across tumor types and, in a single CD19-negative relapse of B-cell acute lymphoblastic leukemia, remained expressed after CD19 CAR T-cell therapy. Thus, CD24 has potential both as a pan-cancer target and as a second-line or combinatorial target following antigen escape. Notably, the antigen recognition domain of the CAR, typically a single chain variable fragment (scFv) of an antibody, is a critical determinant of CAR specificity and function. We here, therefore, performed a head-to-head comparison of four CD24 second-generation 4-1BB CAR T-cells differing only in their scFv clone, specifically clones H2L3, SWA11 and GB7011–05 recognizing the protein core of CD24 and clone SN3 recognizing a CD24 glyco-epitope. The H2L3-derived CAR T-cells displayed high basal IFN-γ production whereas the SWA11-derived CAR T-cells were cytotoxic against cell lines with undetectable CD24 expression. The SN3- and GB7011–05 derived CARs were CD24-specific, and phenotypically equivalent, making them both promising candidates for further exploitation.
No takes yet. Share an insight, caveat, or question.
Lysandrou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: